Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Dehydrocorydaline
Cat. No.:
OB0225LY-0272
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Dehydrocorydaline stimulates p38 MAPK activation, which enhances heterodimerization of MyoD and E proteins, and it also has anti-inflammatory and analgesic effects.
Synonym:
Dehydrocorydalin; 13-Methylpalmatine; 30045-16-0; 2,3,9,10-Tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium; 7,8,13,13a-Tetradehydro-2,3,9,10-tetramethoxy-13-methylberbinium
CAS No.:
30045-16-0
Compound CID:
34781
Formula:
C22H24NO4
Formula Weight:
366.43
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Dehydrocorydaline can be used as a candidate compound for new drug development.
Library Information
Targets:
BCL family; Caspase family; MAPK family; Poly(ADP-ribose) polymerase family
Receptors:
Bcl-2; Caspase; p38 MAPK; PARP
Pathways:
Proteases/Proteasome; Autophagy; Apoptosis; Chromatin/Epigenetic; MAPK; Microbiology/Virology; DNA damage/DNA repair
Plate Number:
AOCL-4
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
66 mg/mL; 180.1 mM
Solubility:
Soluble in chloroform, dichloromethane, ethyl acetate, acetone, etc.
